Valuation: NeoGenomics, Inc.

Market Cap 1.74B 1.53B 1.43B 1.31B 2.46B 167B 2.5B 16.92B 6.62B 82.67B 6.55B 6.41B 286B P/E 2026 *
-30.1x
P/E 2027 * -46.7x
Enterprise Value 1.74B 1.53B 1.43B 1.31B 2.46B 167B 2.5B 16.92B 6.62B 82.67B 6.55B 6.41B 286B EV / Sales 2026 *
2.18x
EV / Sales 2027 * 1.98x
Free-Float
97.95%
Yield 2026 *
-
Yield 2027 * -
1 day+1.98%
1 week-7.27%
Current month-8.16%
1 month-5.43%
3 months+48.56%
6 months+8.24%
Current year+13.95%
1 week 13.05
Extreme 13.05
14.65
1 month 13.05
Extreme 13.05
15.57
Current year 7.06
Extreme 7.065
15.57
1 year 4.72
Extreme 4.72
15.57
3 years 4.72
Extreme 4.72
21.22
5 years 4.72
Extreme 4.72
54.74
10 years 4.72
Extreme 4.72
61.57
Manager TitleAgeSince
Chief Executive Officer 65 2025-03-31
Director of Finance/CFO 57 2026-03-01
President 53 2025-03-31
Director TitleAgeSince
Chairman 64 2021-10-06
Director/Board Member 63 2017-07-18
Director/Board Member 69 2020-07-14
Date Insider Type Main position Quantity % Market Cap.
6/23/26 Free

Director

23,909 0.0184%
6/15/26 Sell

Chairman

-5,307 0.0041%
6/9/26 Sell

Chairman

-5,307 0.0041%
Change 5-day change 1-year change 3-year change Capi.($)
+1.98%-7.27%+107.43%-22.36% 1.74B
-2.25%-5.60%+82.77%+449.74% 36.12B
+4.34%+12.47%+19.99%+46.40% 25.77B
+3.23%+9.23%-19.40%-35.36% 7.59B
+2.78%+2.18%+9.32%+94.70% 4.97B
+4.28%+10.80%+24.41%+61.84% 3.16B
+2.21%+0.37%-27.12%+766.67% 1.84B
+0.42%-0.60%-11.97%-63.14% 1.82B
+3.21%+3.08%+18.31%+6.16% 1.81B
+0.95%+4.49%+22.53%+205.30% 1.46B
Average +2.12%+1.44%+22.63%+150.99% 8.63B
Weighted average by Cap. +1.13%+1.96%+42.45%+224.92%

Financials

2026 *2027 *
Net sales 801M 703M 654M 602M 1.13B 76.51B 1.15B 7.76B 3.04B 37.94B 3.01B 2.94B 131B 881M 773M 720M 662M 1.24B 84.18B 1.26B 8.54B 3.34B 41.75B 3.31B 3.24B 144B
Net income -57.81M -50.74M -47.25M -43.46M -81.46M -5.52B -82.86M -561M -219M -2.74B -217M -212M -9.46B -37.05M -32.51M -30.28M -27.85M -52.2M -3.54B -53.1M -359M -141M -1.76B -139M -136M -6.06B
Net Debt - -
Logo NeoGenomics, Inc.
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others.
Employees
2,500
Date Price Change Volume
26-07-28 US$13.40 +1.98% 2,402,643
26-07-27 US$13.14 -5.40% 1,795,795
26-07-24 US$13.89 -2.46% 1,992,873
26-07-23 US$14.24 +1.64% 1,901,395
26-07-22 US$14.01 -3.04% 1,708,800
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
13.40USD
Average target price
16.78USD
Spread / Average Target
+25.21%

Quarterly revenue - Rate of surprise